Abiomed Announces Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Piper Jaffray Raises Price Target as Abiomed's (ABMD) Results Fall In-line with Preliminary Release
February 5, 2016 9:02 AM ESTPiper Jaffray reiterated a Neutral rating on ABIOMED (NASDAQ: ABMD), and raised the price target to $90.00 (from $75.00), following the company's 3Q earnings report. Results included revenue of $85.8M, representing ~38% y/y growth. ABMD provided updated guidance and raised its FY16 expected revenues to at or slightly better than $326M up from... More
